On Friday, Following Biotechnology Stocks were among the “Top Losers” In U.S. Stock Exchange: Nanosphere, (NASDAQ:NSPH), Organovo Holdings (NYSEMKT:ONVO), Idera Pharmaceuticals (NASDAQ:IDRA), Gilead Sciences, (NASDAQ:GILD), Lexicon Pharmaceuticals, (NASDAQ:LXRX)
On March 25, 2015 Nanosphere, Inc. (NASDAQ:NSPH) a company enhancing medicine through targeted molecular diagnostics, and Scripps Health, a private, nonprofit, integrated health system in San Diego, California, promulgated publication of a study that demonstrates the clinical and economic impact of implementing rapid sepsis diagnostic testing with the Company’s FDA-cleared Verigene(R) Gram-Positive Blood Culture Test (BC-GP) in combination with Antimicrobial Stewardship Team (AST) intervention.
Nanosphere, Inc. (NASDAQ:NSPH)’s shares picked down -7.78%, and closed at $0.228. The stock volatility for the week is 7.38%, while for the month remained 10.80%.
If we consider EPS growth of the company, then the company indicated the following observations:
The company showed -0.48 diluted EPS growth for trailing twelve months. However, YTD EPS growth remained 16.10% and Annual EPS growth for the past 5 years is considered as 20.30%.
The mean recommendation of analysts for this stock is 2.00. (Where 1=Buy, 5=Sale).
Nanosphere, Inc. (NASDAQ:NSPH) develops, manufactures, and markets molecular diagnostic tests that can lead to earlier disease detection, optimal patient treatment, and enhanced healthcare economics.
Organovo Holdings Inc (NYSEMKT:ONVO) is offering the following market update: Organovo remains extremely excited about the early commercial success of our exVive3D™ Human Liver Tissue and we continue to believe it has a strong commercial future in front of it. Nothing has changed from the Company’s perspective, nor are we in possession of any new information that would dampen our optimism about the future of our exVive3D™ Human Liver Tissue or the future of Organovo.
Organovo Holdings Inc (NYSEMKT:ONVO) declined -6.87%, and closed at $3.66. The company has the market capitalization of $316.20 million. The beta value of the stock is 1.38. On the other hand the stock’s volatility for the week is 7.41%, and for the month is 7.67%. The stock’s price to book ratio is $6.10, however price to sale ratio is $736.12. Analyst’s mean recommendation regarding this stock is 3.00. (Where 1=Buy, 5=Sale).
Organovo Holdings Inc (NYSEMKT:ONVO) a development-stage company, focuses on developing and commercializing functional human tissues that could be employed in drug discovery and development, biological research, and as therapeutic implants for the treatment of damaged or degenerating tissues and organs.
Idera Pharmaceuticals Inc (NASDAQ:IDRA) a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for oncology and rare diseases, unveiled its financial and operational results for the fourth quarter and year ended December 31, 2014. For 2015 we look forward to begin delivering clinical results commencing in the fourth quarter from our Phase 1/2 clinical trial of IMO-8400 in Waldenstrom’s macroglobulinemia. In addition, we are now working to rapidly advance our targeted immuno-oncology program into the clinic and also expect to commence clinical development in our rare diseases program by initiating a Phase 2 clinical trial of IMO-8400 in dermatomyositis and DMD by the end of 2015 and early 2016, respectively. We also plan to complete our Phase 1 healthy volunteer trial with IMO-9200 during the year. Finally, we are planning to conduct disease model studies and begin IND-enabling development programs in each of the first two disease indications selected for further development in our gene silencing oligonucleotide, or GSO, program in the second half of 2015.
Idera Pharmaceuticals Inc (NASDAQ:IDRA) decreased -1.86%, and closed at $3.42. The company holds the market capitalization of $411.25 million. For the last twelve months, the stock was able to keep return on equity at -72.60%, while return on assets at -56.90%. Its 20-day moving average decreased -21.92%, below 50-day moving average of -23.33%, below 200-day moving average of 3.04% from the latest market price of $3.42. The mean recommendation of analysts for this stock is 2.00. (Where 1=Buy, 5=Sale).
Idera Pharmaceuticals Inc (NASDAQ:IDRA) a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for oncology and rare diseases in the United States.
Gilead Sciences, Inc. (NASDAQ:GILD) disclosed that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved Sovaldi® (sofosbuvir), a once-daily nucleotide analog polymerase inhibitor, for the suppression of viremia in patients with genotype 2 chronic hepatitis C virus (HCV) infection with or without compensated cirrhosis. Sovaldi is indicated for use in combination with ribavirin (RBV) for 12 weeks. Sovaldi (in combination with RBV) is the first all-oral, interferon-free treatment regimen for genotype 2 HCV infection. Sovaldi is also the first product to be marketed by Gilead in Japan.
Gilead Sciences, Inc. (NASDAQ:GILD) fell -0.07%, and closed at $101.00. The stock has the beta value of 0.71, and its volatility for the week is 2.51%, while for the month it is 1.95%. The company has the market capitalization of $150.43 billion. The company holds the book value per share of 10.25, whereas cash per share is 6.80. Price to book ratio remained 9.85, while price to sale ratio is 6.04. Analysts mean recommendation for the stock is said to be 1.80 (where 1=Buy, 5=sale).
Gilead Sciences, Inc. (NASDAQ:GILD) a biopharmaceutical company, discovers, develops, and commercializes medicines in areas of unmet medical nee in North America, South America, Europe, and the Asia-Pacific. The company’s products include Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, Tybost, and Vitekta for the treatment of human immunodeficiency virus (HIV) infection in adults; and Harvoni, Sovaldi, Viread, and Hepsera products for the treatment of liver disease.
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX), uncovered that it has commenced screening in its first pivotal Phase 3 clinical trial of sotagliflozin for type 1 diabetes. Lexicon will be conducting two pivotal Phase 3 clinical trials of sotagliflozin, one in North America and another primarily in Europe. Each pivotal trial is a randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate the efficacy, safety and tolerability of sotagliflozin in adult patients with type 1 diabetes. Two dose levels of sotagliflozin, 200mg and 400mg once daily, will be tested along with placebo.
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) decreased -0.16%, and closed at $0.951. The stock has the beta value of 1.97, and its volatility for the week is 5.80%, while for the month it is 5.43%. The company has the market capitalization of $689.28 million. The company holds the book value per share of 0.48, whereas cash per share is 0.47. Price to book ratio remained 1.98, while price to sale ratio is 30.10. Analysts mean recommendation for the stock is said to be 2.10 (where 1=Buy, 5=sale).
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) a biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of human diseases. Its drug development programs include telotristat etiprate, an orally-delivered small molecule drug candidate, which is in Phase III clinical trials for the treatment of carcinoid syndrome.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The data demonstrated in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
